Comparative Pharmacology
Head-to-head clinical analysis: CIDA STAT versus PHISOHEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIDA STAT versus PHISOHEX.
CIDA-STAT vs PHISOHEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIDA-STAT is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol levels.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
10 mg orally once daily
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
None Documented
None Documented
Terminal half-life: 12-15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Renal: 30% unchanged; Biliary/fecal: 60% as metabolites; 10% other
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Category C
Category C
Antiseptic
Antiseptic